GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Suzhou Fushilai Pharmaceutical Co Ltd (SZSE:301258) » Definitions » Debt-to-Revenue

Suzhou Fushilai Pharmaceutical Co (SZSE:301258) Debt-to-Revenue : 0.00 (As of Mar. 2025)


View and export this data going back to 2022. Start your Free Trial

What is Suzhou Fushilai Pharmaceutical Co Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Suzhou Fushilai Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ¥0.7 Mil. Suzhou Fushilai Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ¥0.8 Mil. Suzhou Fushilai Pharmaceutical Co's annualized Revenue for the quarter that ended in Mar. 2025 was ¥452.3 Mil. Suzhou Fushilai Pharmaceutical Co's annualized Debt-to-Revenue for the quarter that ended in Mar. 2025 was 0.00.


Suzhou Fushilai Pharmaceutical Co Debt-to-Revenue Historical Data

The historical data trend for Suzhou Fushilai Pharmaceutical Co's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suzhou Fushilai Pharmaceutical Co Debt-to-Revenue Chart

Suzhou Fushilai Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.04 0.01 0.01 -

Suzhou Fushilai Pharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 - 0.01 - -

Competitive Comparison of Suzhou Fushilai Pharmaceutical Co's Debt-to-Revenue

For the Biotechnology subindustry, Suzhou Fushilai Pharmaceutical Co's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Suzhou Fushilai Pharmaceutical Co's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Suzhou Fushilai Pharmaceutical Co's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Suzhou Fushilai Pharmaceutical Co's Debt-to-Revenue falls into.


;
;

Suzhou Fushilai Pharmaceutical Co Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Suzhou Fushilai Pharmaceutical Co's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.656 + 1.01) / 429.468
=0.00

Suzhou Fushilai Pharmaceutical Co's annualized Debt-to-Revenue for the quarter that ended in Mar. 2025 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.678 + 0.836) / 452.336
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2025) Revenue data.


Suzhou Fushilai Pharmaceutical Co Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Suzhou Fushilai Pharmaceutical Co's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Suzhou Fushilai Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No. 16, Haiwang Road, New Material Industrial Park, Jiangsu Province, Changshu, CHN, 215500
Suzhou Fushilai Pharmaceutical Co Ltd is engaged in the Research and development, production and sales of pharmaceutical intermediates, APIs and raw materials for health care products. The products are mainly used in the fields of medicine, dietary supplements and cosmetics, and have significant effects in anti-oxidation, anti-aging, and blood sugar improvement.
Executives
Qian Yi Supervisors

Suzhou Fushilai Pharmaceutical Co Headlines

No Headlines